Overall survival
| Study ID | Donor group (MSD-HSCT) | No donor group (IST) | FU* | p Value | ||
|---|---|---|---|---|---|---|
| N | OS (95% CI), % | N | OS (95% CI), % | Year | ||
| Bayever et al20 | 35 | 72 (64 to 80) | 22 | 45 (29 to 61) | 2 | 0.18 |
| Führer et al22 | 28 | 84 (NR) | 86 | 87 (NR) | 4 | 0.43 |
| Gratwohl et al21 | 19 | 47 (NR) | 13 | 69† (NR) | 5 | 0.56‡ |
*Time point of Kaplan-Meier estimate.
†Gratwohl et al21: 2 of 13 patients were eligible for MSD-HSCT but donors were not available in the first place; the two patients died after they received a second-line HSCT from the then again available MSD that was offered after the patients showed no response to IST.
‡The p value was not reported and we calculated the p value using Fisher’s exact test.
FU, follow-up; IST, immunosuppressive therapy including ciclosporin and/or antithymocyte or antilymphocyte globulin; MSD-HSCT, first-line allogeneic haematopoietic stem cell transplantation from HLA-matched sibling donor; N, number of analysed patients; NR, not reported; OS, overall survival.